Janssen H L, Kerhof-Los C J, Heijtink R A, Schalm S W
Department of Internal Medicine II, University Hospital Dijkzigt, Rotterdam, The Netherlands.
Antiviral Res. 1994 Apr;23(3-4):251-7. doi: 10.1016/0166-3542(94)90022-1.
HBsAg was measured quantitatively in serum samples collected serially before and after the HBeAg seroconversion date from 69 patients with HBeAg seroconversion and 17 patients with both HBeAg and HBsAg seroconversion. In patients with only HBeAg seroconversion the median HBsAg level decreased from 8.39 micrograms/ml (range 0.01-57.51) before HBeAg seroconversion to 3.53 micrograms/ml (range 0.002-68.66) after seroconversion (P < 0.001). No significant drop in HBsAg was found for the control group (18 HBeAg-positive patients without seroconversion). From 12 other patients on alpha-interferon therapy HBsAg was quantitatively assayed monthly during and after therapy; HBsAg levels were compared to the levels of HBV-DNA and HBeAg. We observed a good correlation between the HBsAg level and both the HBV-DNA (r = 0.76; P < 0.001) and the HBeAg (r = 0.70; P < 0.001) level, irrespective of the response to alpha-interferon. Quantified assessment of HBsAg appears promising as a simple and cheap method for monitoring viral replication in chronic hepatitis B in patients undergoing interferon therapy.
对69例HBeAg血清学转换患者以及17例HBeAg和HBsAg均发生血清学转换的患者，在HBeAg血清学转换日期前后连续采集的血清样本中对HBsAg进行定量检测。在仅发生HBeAg血清学转换的患者中，HBsAg水平中位数从HBeAg血清学转换前的8.39微克/毫升（范围0.01 - 57.51）降至血清学转换后的3.53微克/毫升（范围0.002 - 68.66）（P < 0.001）。对照组（18例未发生血清学转换的HBeAg阳性患者）未发现HBsAg有显著下降。对另外12例接受α干扰素治疗的患者在治疗期间及治疗后每月进行HBsAg定量检测；将HBsAg水平与HBV - DNA和HBeAg水平进行比较。我们观察到，无论对α干扰素的反应如何，HBsAg水平与HBV - DNA（r = 0.76；P < 0.001）和HBeAg（r = 0.70；P < 0.001）水平均具有良好的相关性。对HBsAg进行定量评估，作为一种简单且廉价的方法，有望用于监测接受干扰素治疗的慢性乙型肝炎患者的病毒复制情况。
